Last reviewed · How we verify

methylcantharidimide tablets — Competitive Intelligence Brief

methylcantharidimide tablets (methylcantharidimide tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PP2A inhibitor; anti-tumor agent. Area: Oncology.

marketed PP2A inhibitor; anti-tumor agent Protein phosphatase 2A (PP2A) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

methylcantharidimide tablets (methylcantharidimide tablets) — Suzhou Municipal Hospital. Methylcantharidimide is a cantharidin derivative that induces apoptosis and inhibits protein phosphatase 2A (PP2A), leading to anti-tumor effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
methylcantharidimide tablets TARGET methylcantharidimide tablets Suzhou Municipal Hospital marketed PP2A inhibitor; anti-tumor agent Protein phosphatase 2A (PP2A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PP2A inhibitor; anti-tumor agent class)

  1. Suzhou Municipal Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). methylcantharidimide tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/methylcantharidimide-tablets. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: